Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Short-term Investments: 2021-2024

Historic Short-term Investments for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $60.0 million.

  • Kiniksa Pharmaceuticals International's Short-term Investments rose 40.22% to $177.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.2 million, marking a year-over-year increase of 40.22%. This contributed to the annual value of $60.0 million for FY2024, which is 38.99% down from last year.
  • Kiniksa Pharmaceuticals International's Short-term Investments amounted to $60.0 million in FY2024, which was down 38.99% from $98.4 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Short-term Investments registered a high of $98.4 million during FY2023, and its lowest value of $59.7 million during FY2021.
  • Moreover, its 3-year median value for Short-term Investments was $67.9 million (2022), whereas its average is $75.5 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 44.96% in 2023, then slumped by 38.99% in 2024.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Short-term Investments stood at $59.7 million in 2021, then increased by 13.66% to $67.9 million in 2022, then soared by 44.96% to $98.4 million in 2023, then slumped by 38.99% to $60.0 million in 2024.